{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:13:55Z","timestamp":1778840035594,"version":"3.51.4"},"reference-count":68,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["10266824"],"award-info":[{"award-number":["10266824"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-17-1-0475"],"award-info":[{"award-number":["W81XWH-17-1-0475"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["L40AR070539"],"award-info":[{"award-number":["L40AR070539"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["L40NS127380"],"award-info":[{"award-number":["L40NS127380"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["R01HL153054"],"award-info":[{"award-number":["R01HL153054"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","award":["1069118"],"award-info":[{"award-number":["1069118"]}],"id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R00HL130035"],"award-info":[{"award-number":["R00HL130035"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["L40AR068727"],"award-info":[{"award-number":["L40AR068727"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001625","name":"Foundation to Eradicate Duchenne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.omtn.2024.102228","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T13:20:14Z","timestamp":1716556814000},"page":"102228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Deletion of miR-146a enhances therapeutic protein restoration in model of dystrophin exon skipping"],"prefix":"10.1016","volume":"35","author":[{"given":"Nikki M.","family":"McCormack","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelsey A.","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina M.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher B.","family":"Tully","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Heier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3458-8036","authenticated-orcid":false,"given":"Alyson A.","family":"Fiorillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2024.102228_bib1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2024.102228_bib2","first-page":"54","article-title":"Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies","volume":"49","author":"Beggs","year":"1991","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtn.2024.102228_bib3","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1212\/WNL.39.8.1011","article-title":"Improved diagnosis of Becker muscular dystrophy by dystrophin testing","volume":"39","author":"Hoffman","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2024.102228_bib4","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/humu.20722","article-title":"Integrated DNA, cDNA, and protein studies in Becker muscular dystrophy show high exception to the reading frame rule","volume":"29","author":"Kesari","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2024.102228_bib5","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/jnnp-2013-306350","article-title":"Dystrophin levels and clinical severity in Becker muscular dystrophy patients","volume":"85","author":"van den Bergen","year":"2014","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.omtn.2024.102228_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-16170-2","article-title":"Muscle MRI and functional outcome measures in Becker muscular dystrophy","volume":"7","author":"Barp","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2024.102228_bib7","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.celrep.2015.07.066","article-title":"TNF-alpha-Induced microRNAs Control Dystrophin Expression in Becker Muscular Dystrophy","volume":"12","author":"Fiorillo","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2024.102228_bib8","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/jcsm.13171","article-title":"The X-linked Becker muscular dystrophy (bmx) mouse models Becker muscular dystrophy via deletion of murine dystrophin exons 45-47","volume":"14","author":"Heier","year":"2023","journal-title":"J.\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.omtn.2024.102228_bib9","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2024.102228_bib10","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2024.102228_bib11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/mus.27347","article-title":"Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial","volume":"64","author":"Wagner","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtn.2024.102228_bib12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3233\/JND-221656","article-title":"Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study","volume":"10","author":"Clemens","year":"2023","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.omtn.2024.102228_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/nat.2021.0043","article-title":"Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1\/2 Trial","volume":"32","author":"Servais","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2024.102228_bib14","unstructured":"Study of Eteplirsen in DMD Patients (PROMOVI) ClinicalTrials.gov."},{"key":"10.1016\/j.omtn.2024.102228_bib15","doi-asserted-by":"crossref","first-page":"17016","DOI":"10.1073\/pnas.0708115104","article-title":"Distinctive patterns of microRNA expression in primary muscular disorders","volume":"104","author":"Eisenberg","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2024.102228_bib16","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/embor.2010.208","article-title":"miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy","volume":"12","author":"Cacchiarelli","year":"2011","journal-title":"EMBO Rep."},{"key":"10.1016\/j.omtn.2024.102228_bib17","doi-asserted-by":"crossref","first-page":"16961","DOI":"10.1073\/pnas.0506482102","article-title":"MicroRNAs control translation initiation by inhibiting eukaryotic initiation factor 4E\/cap and poly(A) tail function","volume":"102","author":"Humphreys","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2024.102228_bib18","doi-asserted-by":"crossref","first-page":"12481","DOI":"10.1073\/pnas.0605298103","article-title":"NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses","volume":"103","author":"Taganov","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2024.102228_bib19","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1038\/ctg.2016.49","article-title":"Identification of Pathway-Specific Serum Biomarkers of Response to Glucocorticoid and Infliximab Treatment in Children with Inflammatory Bowel Disease","volume":"7","author":"Heier","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.omtn.2024.102228_bib20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1152\/physiolgenomics.00134.2017","article-title":"Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone","volume":"50","author":"Fiorillo","year":"2018","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.omtn.2024.102228_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107161","article-title":"Vamorolone improves Becker muscular dystrophy and increases dystrophin protein in bmx model mice","volume":"26","author":"McCormack","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.omtn.2024.102228_bib22","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/art.41215","article-title":"Muscle Weakness in Myositis: MicroRNA-Mediated Dystrophin Reduction in a Myositis Mouse Model and Human Muscle Biopsies","volume":"72","author":"Kinder","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.omtn.2024.102228_bib23","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.049016","article-title":"Identification of candidate miRNA biomarkers for facioscapulohumeral muscular dystrophy using DUX4-based mouse models","volume":"14","author":"Nunes","year":"2021","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.omtn.2024.102228_bib24","article-title":"Rheumatoid Arthritis and miRNAs: A Critical Review through a Functional View","volume":"2018","author":"Moran-Moguel","year":"2018","journal-title":"J.\u00a0Immunol. Res."},{"key":"10.1016\/j.omtn.2024.102228_bib25","article-title":"MicroRNA in Sj\u00f6gren's Syndrome: Their Potential Roles in Pathogenesis and Diagnosis","volume":"2018","author":"Reale","year":"2018","journal-title":"J.\u00a0Immunol. Res."},{"key":"10.1016\/j.omtn.2024.102228_bib26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/1756283X14547360","article-title":"The emerging role of miRNAs in inflammatory bowel disease: a review","volume":"8","author":"Chapman","year":"2015","journal-title":"Therap. Adv. Gastroenterol."},{"key":"10.1016\/j.omtn.2024.102228_bib27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.coi.2015.07.006","article-title":"MicroRNA regulation of allergic inflammation and asthma","volume":"36","author":"Pua","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.omtn.2024.102228_bib28","first-page":"246","article-title":"Aberrant Expression of Immune-related MicroRNAs in Pediatric Patients with Asthma","volume":"9","author":"Elnady","year":"2020","journal-title":"Int. J. Mol. Cell. Med."},{"key":"10.1016\/j.omtn.2024.102228_bib29","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1093\/bioinformatics\/btac110","article-title":"scanMiR: a biochemically based toolkit for versatile and efficient microRNA target prediction","volume":"38","author":"Soutschek","year":"2022","journal-title":"Bioinformatics"},{"key":"10.1016\/j.omtn.2024.102228_bib30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.molcel.2007.06.017","article-title":"MicroRNA targeting specificity in mammals: determinants beyond seed pairing","volume":"27","author":"Grimson","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omtn.2024.102228_bib31","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1083\/jcb.148.5.985","article-title":"Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion","volume":"148","author":"Lu","year":"2000","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.omtn.2024.102228_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069194","article-title":"Mutation types and aging differently affect revertant fiber expansion in dystrophic mdx and mdx52 mice","volume":"8","author":"Echigoya","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2024.102228_bib33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13395-015-0070-6","article-title":"Elusive sources of variability of dystrophin rescue by exon skipping","volume":"5","author":"Vila","year":"2015","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omtn.2024.102228_bib34","doi-asserted-by":"crossref","first-page":"S383","DOI":"10.3233\/JND-210696","article-title":"Interrogation of Dystrophin and Dystroglycan Complex Protein Turnover After Exon Skipping Therapy","volume":"8","author":"Novak","year":"2021","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.omtn.2024.102228_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195850","article-title":"Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy","volume":"13","author":"Beekman","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2024.102228_bib36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nm1345","article-title":"Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology","volume":"12","author":"Alter","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2024.102228_bib37","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/ana.21627","article-title":"Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs","volume":"65","author":"Yokota","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2024.102228_bib38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2990.1988.tb00866.x","article-title":"The mdx mouse skeletal muscle myopathy: I. A histological, morphometric and biochemical investigation","volume":"14","author":"Coulton","year":"1988","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.omtn.2024.102228_bib39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1083\/jcb.201402079","article-title":"Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy","volume":"207","author":"Dadgar","year":"2014","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.omtn.2024.102228_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103441","article-title":"Role of extracellular microRNA-146a-5p in host innate immunity and bacterial sepsis","volume":"24","author":"Wang","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.omtn.2024.102228_bib41","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/abbs\/gmx052","article-title":"miR-146a-5p acts as a negative regulator of TGF-beta signaling in skeletal muscle after acute contusion","volume":"49","author":"Sun","year":"2017","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.omtn.2024.102228_bib42","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1194\/jlr.M062497","article-title":"miR-146a-5p inhibits TNF-alpha-induced adipogenesis via targeting insulin receptor in primary porcine adipocytes","volume":"57","author":"Wu","year":"2016","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.omtn.2024.102228_bib43","article-title":"miR-146a-5p targets Sirt1 to regulate bone mass","volume":"14","author":"Zheng","year":"2021","journal-title":"Bone Rep."},{"key":"10.1016\/j.omtn.2024.102228_bib44","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.2353\/ajpath.2008.071042","article-title":"Preservation of muscle force in Mdx3cv mice correlates with low-level expression of a near full-length dystrophin protein","volume":"172","author":"Li","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omtn.2024.102228_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015286","article-title":"Marginal level dystrophin expression improves clinical outcome in a strain of dystrophin\/utrophin double knockout mice","volume":"5","author":"Li","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2024.102228_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031937","article-title":"The effects of low levels of dystrophin on mouse muscle function and pathology","volume":"7","author":"van Putten","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2024.102228_bib47","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/hmg\/4.8.1251","article-title":"Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice","volume":"4","author":"Phelps","year":"1995","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2024.102228_bib48","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1093\/hmg\/ddv155","article-title":"How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse","volume":"24","author":"Godfrey","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2024.102228_bib49","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omtn.2024.102228_bib50","article-title":"Investigating Synthetic Oligonucleotide Targeting of Mir31 in Duchenne Muscular Dystrophy","volume":"8","author":"Hildyard","year":"2016","journal-title":"PLoS Curr."},{"key":"10.1016\/j.omtn.2024.102228_bib51","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/ibd\/izaa209","article-title":"Serum miRNAs Are Pharmacodynamic Biomarkers Associated With Therapeutic Response in Pediatric Inflammatory Bowel Disease","volume":"26","author":"Batra","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.omtn.2024.102228_bib52","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1084\/jem.20101823","article-title":"miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice","volume":"208","author":"Boldin","year":"2011","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omtn.2024.102228_bib53","doi-asserted-by":"crossref","first-page":"34590","DOI":"10.1074\/jbc.M109.056317","article-title":"miR-146a is critical for endotoxin-induced tolerance: IMPLICATION IN INNATE IMMUNITY","volume":"284","author":"Nahid","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2024.102228_bib54","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41587-022-01517-6","article-title":"Spatial mapping of the total transcriptome by in\u00a0situ polyadenylation","volume":"41","author":"McKellar","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2024.102228_bib55","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13395-019-0207-0","article-title":"miR-146a deficiency does not aggravate muscular dystrophy in mdx mice","volume":"9","author":"Bronisz-Budzynska","year":"2019","journal-title":"Skelet Muscle"},{"key":"10.1016\/j.omtn.2024.102228_bib56","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00401-023-02619-4","article-title":"Decreased dystrophin expression and elevated dystrophin-targeting miRNAs in anti-HMGCR immune-mediated necrotizing myopathy","volume":"146","author":"Marmen","year":"2023","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.omtn.2024.102228_bib57","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.tig.2022.02.006","article-title":"Emerging concepts of miRNA therapeutics: from cells to clinic","volume":"38","author":"Diener","year":"2022","journal-title":"Trends Genet."},{"key":"10.1016\/j.omtn.2024.102228_bib58","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/eurheartj\/ehaa898","article-title":"Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study","volume":"42","author":"Taubel","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.omtn.2024.102228_bib59","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/apt.13432","article-title":"Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma","volume":"43","author":"van der Ree","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.omtn.2024.102228_bib60","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1089\/nat.2020.0871","article-title":"Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study","volume":"30","author":"Abplanalp","year":"2020","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2024.102228_bib61","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.omtn.2020.07.021","article-title":"Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy","volume":"21","author":"Cerro-Herreros","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2024.102228_bib62","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.omtn.2022.02.003","article-title":"Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model","volume":"27","author":"Overby","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2024.102228_bib63","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1006\/bbrc.1997.7328","article-title":"Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy","volume":"238","author":"Araki","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtn.2024.102228_bib64","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.cell.2010.08.012","article-title":"Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses","volume":"142","author":"Lu","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2024.102228_bib65","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1073\/pnas.98.1.42","article-title":"Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse","volume":"98","author":"Mann","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2024.102228_bib66","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1038\/mt.2010.186","article-title":"In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse","volume":"18","author":"Aoki","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2024.102228_bib67","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2002-3-7-research0034","article-title":"Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes","volume":"3","author":"Vandesompele","year":"2002","journal-title":"Genome Biol."},{"key":"10.1016\/j.omtn.2024.102228_bib68","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.omtm.2022.07.005","article-title":"Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse","volume":"26","author":"Wein","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S216225312400115X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S216225312400115X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:56:03Z","timestamp":1778838963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S216225312400115X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S216225312400115X"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2024.102228","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.05.09.540042","asserted-by":"object"}]},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deletion of miR-146a enhances therapeutic protein restoration in model of dystrophin exon skipping","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2024.102228","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102228"}}